Key Topics Not to be Missed at the Ophthalmic Drugs Conference
SAE Media Group reports: join ophthalmic professionals for the Ophthalmic Drugs Conference this November.
Stay updated with breaking news from Late Stage Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAE Media Group reports: join ophthalmic professionals for the Ophthalmic Drugs Conference this November.
The FDA has accepted for priority review Seagen’s sNDA seeking accelerated approval for its tukysa along with trastuzumab to treat colorectal cancer.
The FDA has accepted for Priority Review the sNDA for tucatinib plus trastuzumab for adults with HER2-positive colorectal cancer.
– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –– Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 –BOTHELL, Wash. & TOKYO & RAHWAY, N.J.--(BU...
– Results from EV-103 trial evaluating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in urothelial cancer to be featured as late-breaking oral session –BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development progra...